763 related articles for article (PubMed ID: 28739795)
1. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.
Choi H; Kim SY; Kim DH; Huh HJ; Ki CS; Lee NY; Lee SH; Shin S; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739795
[TBL] [Abstract][Full Text] [Related]
2. Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report.
Kim SY; Shin SJ; Jeong BH; Koh WJ
BMC Infect Dis; 2016 May; 16():207. PubMed ID: 27188784
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease.
Choi H; Jhun BW; Kim SY; Kim DH; Lee H; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Diagn Microbiol Infect Dis; 2018 Apr; 90(4):293-295. PubMed ID: 29329759
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease.
Choi H; Kim SY; Lee H; Jhun BW; Park HY; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Lee SH; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872066
[TBL] [Abstract][Full Text] [Related]
5. Association between sequevar and antibiotic treatment outcome in patients with Mycobacterium abscessus complex infections in Japan.
Yoshida S; Tsuyuguchi K; Kobayashi T; Tomita M; Inoue Y; Hayashi S; Suzuki K
J Med Microbiol; 2018 Jan; 67(1):74-82. PubMed ID: 29227218
[TBL] [Abstract][Full Text] [Related]
6. Impact on Macrolide Resistance of Genetic Diversity of Mycobacterium abscessus Species.
Jong BE; Wu TS; Chen NY; Yang CH; Shu CC; Wang LS; Wu TL; Lu JJ; Chiu CH; Lai HC; Chung WH
Microbiol Spectr; 2022 Dec; 10(6):e0274922. PubMed ID: 36416559
[TBL] [Abstract][Full Text] [Related]
7. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections.
Jeong SH; Kim SY; Huh HJ; Ki CS; Lee NY; Kang CI; Chung DR; Peck KR; Shin SJ; Koh WJ
Int J Infect Dis; 2017 Jul; 60():49-56. PubMed ID: 28522316
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.
Moon SM; Park HY; Kim SY; Jhun BW; Lee H; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2016 Nov; 60(11):6758-6765. PubMed ID: 27572413
[TBL] [Abstract][Full Text] [Related]
9. [In vitro Activity of Rifabutin and Clofazimine to Macrolide-Resistant Mycobacterium abscessus Complex Clinical Isolates].
Sürücüoğlu S; Özkütük N; Gazi H; Çavuşoğlu C
Mikrobiyol Bul; 2023 Oct; 57(4):639-649. PubMed ID: 37885391
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease.
Koh WJ; Jeong BH; Kim SY; Jeon K; Park KU; Jhun BW; Lee H; Park HY; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Kim H; Kwon OJ
Clin Infect Dis; 2017 Feb; 64(3):309-316. PubMed ID: 28011608
[TBL] [Abstract][Full Text] [Related]
11. Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.
Fujiwara K; Uesugi F; Furuuchi K; Tanaka Y; Yoshiyama T; Saotome M; Ohta K; Mitarai S; Morimoto K
Microbiol Spectr; 2021 Dec; 9(3):e0192821. PubMed ID: 34878300
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.
Pasipanodya JG; Ogbonna D; Ferro BE; Magombedze G; Srivastava S; Deshpande D; Gumbo T
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807911
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Mycobacterium abscessus Pulmonary Disease.
Griffith DE; Daley CL
Chest; 2022 Jan; 161(1):64-75. PubMed ID: 34314673
[TBL] [Abstract][Full Text] [Related]
14. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex.
Koh WJ; Stout JE; Yew WW
Int J Tuberc Lung Dis; 2014 Oct; 18(10):1141-8. PubMed ID: 25216826
[TBL] [Abstract][Full Text] [Related]
15. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.
Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792
[TBL] [Abstract][Full Text] [Related]
16. Noncanonical Mismatch Repair Protein NucS Modulates the Emergence of Antibiotic Resistance in Mycobacterium abscessus.
Fressatti Cardoso R; Martín-Blecua I; Pietrowski Baldin V; Meneguello JE; Valverde JR; Blázquez J; Castañeda-García A
Microbiol Spectr; 2022 Dec; 10(6):e0222822. PubMed ID: 36219122
[TBL] [Abstract][Full Text] [Related]
17.
Cheng A; Tsai YT; Chang SY; Sun HY; Wu UI; Sheng WH; Chen YC; Chang SC
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670428
[TBL] [Abstract][Full Text] [Related]
18. Comparison of drug-susceptibility patterns and gene sequences associated with clarithromycin and azithromycin resistance in
Yoshida S; Tsuyuguchi K; Kobayashi T; Inoue Y; Suzuki K
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33570485
[No Abstract] [Full Text] [Related]
19. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870
[TBL] [Abstract][Full Text] [Related]
20. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
Siegel SAR; Griffith DE; Philley JV; Brown-Elliott BA; Brunton AE; Sullivan PE; Fuss C; Strnad L; Wallace RJ; Winthrop KL
Chest; 2023 Oct; 164(4):846-859. PubMed ID: 37419144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
